Highest 1-Year OS Rate! iza-bren Combined with Sintilimab Achieves 8.2 Months mPFS and 85.7% 1-Year OS Rate in First-Line Extensive-Stage Small Cell Lung Cancer
From March 25 to 28, 2026, at the European Lung Cancer Congress (2026 ELCC) held in Copenhagen, Denmark, the clinical research results of Biokin Pharmaceutical's independently developed iza-bren (EGFR×HER3 bispecific ADC) combined with sintilimab for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) were successfully selected for oral presentation at the congress.